Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of FOXO4-DRI and Vilon — mechanism, side effects, legal status, and pricing.
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. It is studied as a senolytic agent that selectively induces apoptosis in senescent cells while sparing normal cells.
Vilon is a synthetic dipeptide (Lys-Glu / KE) from the Khavinson bioregulator series, originally derived from thymus extracts and studied in Russian preclinical models as an immunomodulator and geroprotector. Not FDA-approved; all published evidence originates from a single research group.
FOXO4-DRI
Vilon
Category
Legal Status
Mechanism
Side Effects
Contraindications
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
FOXO4-DRI
Vilon
COA corpus from Disclosed Labs — independently tested batches only.
FOXO4-DRI
5
COAs
99.5%
Avg purity
4
Labs
Vilon
11
COAs
99.7%
Avg purity
6
Labs
Baar et al. (Cell, 2017, PMID 28340339) identified FOXO4 as a pivot for senescent-cell viability and designed a cell-penetrating D-retro-inverso peptide that disrupts the FOXO4-p53 interaction, selectively triggering apoptosis in senescent cells while sparing proliferating cells. In vivo, the peptide neutralized doxorubicin chemotoxicity and, in fast-aging XpdTTD/TTD and naturally aged mice, restored fur density, renal function, and fitness. This is the only primary in vivo study; evidence is preclinical only. No human clinical trials have been registered or completed. Safety in humans is unknown — as a systemic senolytic inducing apoptosis, theoretical risks include impaired wound healing, immune perturbation, and off-target effects on quiescent stem-cell populations.
Evidence is limited to Khavinson-group preclinical work. Khavinson & Anisimov (Dokl Biol Sci, 2000; PMID 10944717) reported that Vilon (L-Lys-L-Glu) inhibited spontaneous tumor growth and extended lifespan in CBA mice. A small Russian report on Vilon as an adjuvant in elderly colorectal-cancer patients (Kuznik et al., 2005; PMID 16075684) is non-randomized and unreplicated. No Western-framework clinical trials, pharmacokinetic, or dose-response studies have been published.
FOXO4-DRI (Metabolic) and Vilon (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Lab Testing
Disclosed Labs